Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carole D Gleeson

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Nature Reviews. Drug Discovery|March 30, 2004
OmalizumabStephen A Ames, Carole D Gleeson, Peter Kirkpatrick
Alcohol (Fayetteville, N.Y.)|August 11, 2020
Risk factors and costs associated with 30-day readmissions following alcohol-related hospitalizations in the United States from 2010 to 2015Alison R Silverstein, Rebecca Kee, Carole D Gleeson, et al.
CNS Drugs|September 21, 2021
Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of SchizophreniaJohn Lauriello, Peter J Weiden, Carole D Gleeson, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Nature Reviews. Drug Discovery|March 30, 2004
OmalizumabStephen A Ames, Carole D Gleeson, Peter Kirkpatrick
Alcohol (Fayetteville, N.Y.)|August 11, 2020
Risk factors and costs associated with 30-day readmissions following alcohol-related hospitalizations in the United States from 2010 to 2015Alison R Silverstein, Rebecca Kee, Carole D Gleeson, et al.
CNS Drugs|September 21, 2021
Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of SchizophreniaJohn Lauriello, Peter J Weiden, Carole D Gleeson, et al.
Pageof 1